Hemangiomas - current therapeutic strategies

International Journal of Developmental Biology

Volumn 55, Issue 4-5, 2011, Pages 431-437

  Mabeta, Peace ^a   Pepper, Michael S ^b,c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Anti angiogenesis; Bleomycin; Hemangioma; Propranolol; Vincristine

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BETAMETHASONE; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GINSENOSIDE RG 3; HYDROCORTISONE; INTERFERON; METHYLPREDNISOLONE; NADOLOL; PREDNISOLONE; PROPRANOLOL; STEROID; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN HEMANGIOMA; CAPILLARY HEMANGIOMA; COMPLICATION; CONSTIPATION; CUSHINGOID SYNDROME; DRUG POTENTIATION; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; GROWTH RATE; HEMANGIOMA; HUMAN; HYPERPIGMENTATION; HYPERTENSION; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NEUTROPENIA; NONHUMAN; PAIN; PARALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SPASTIC DIPLEGIA; ULCER; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANGIOGENESIS INHIBITORS; BLEOMYCIN; CHILD; CYCLOPHOSPHAMIDE; HEMANGIOMA; HUMANS; INTERFERONS; NEOVASCULARIZATION, PATHOLOGIC; PROPRANOLOL; SKIN NEOPLASMS; STEROIDS; THALIDOMIDE; VINCRISTINE;

EID: 79960991684     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.103221pm     Document Type: Article

References (64)

1. ANNABI B, LACHAMBRE MP, PLOUFFE K, MOUMDJIAN R, BELIVEAU R. (2009). Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60: 38-445.
2. AVRAMIS IA, KWOCK R, AVRAMIS VI. (2001). Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 21: 2281-2286.
3. BANCIU M, SCHIFFELERS RM, FENS MHAM, METSELAAR JM, STORM G. (2006). Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release 113: 1-8.
4. BARLOW CF, PRIEBE CJ, MULLIKEN JB, BARNES PD, MAC DONALD D, FOLKMAN J, EZEKOWITZ RAB. (1998). Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 132: 527-530.
5. BAUER KS, DIXON SC, FIGG WD. (1998). Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827-1834.
6. BLEI F. (2005). Basic science and clinical aspects of vascular anomalies. Curr Opin Pediatr 17: 501-9.
7. BOON LM, BURROWS PE, PALTIEL HJ, LUND DP, EZEKOWITZ RAB, FOLKMAN J, MULLIKEN JB. (1996). Hepatic vascular anomalies in infancy: A twenty-seven-year experience. J Pediatr 129: 346-354.
8. BRUCKNER AL, FRIEDEN IJ. (2003). Hemangiomas of infancy. J Am Acad Dermatol 48: 477-493.
9. CORDORO KM, SPEETZEN LS, KOERPER MA, FRIEDEN IJ. (2009). Physiologic changes in vascular birthmarks during early infancy: Mechanisms and clinical implications. J Am Acad Dermatol 60: 669-675.
10. EBRAHEM Q, MINAMOTO A, HOPPE G, ANAND-APTE B, SEARS JE. (2006). Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci 47: 4935-4941.
11. D'ANGELO G, LEE H, WEINER RI. (1997). cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking raf activation. J Cell Biochem 67: 353-366.
12. ENJOLRAS O and MULLIKEN JB. (1993). The current management of vascular birthmarks. Pediatr Dermatol 10: 311-313.
13. ENJOLRAS O, SOUPRE V, PICARD A. (2008). Uncommon benign infantile vascular tumors. Adv Dermatol 24: 105-124.
14. ENJOLRAS O, BREVIÈRE GM, ROGER G, TOVI M, PELLEGRINO B, VAROTTI E, SOUPRE V, PICARD A, LEVERGER G. (2004). Traitement par vincristine des hémangiomes graves du nourrissonVincristine treatment for function- and life-threatening infantile hemangioma. Arch Pédiatrie 11: 99-107.
15. EZEKOWITZ RA, MULLIKEN JB, FOLKMAN J. (1992). Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 326: 1456-1463.
16. FERNÁNDEZ Y, BERNABEU-WITTEL M, GARCÍA-MORILLO JS. (2009). Kaposiform hemangioendothelioma. Eur J Intern Med 20: 106-113.
17. FOTSIS T, ZHANG Y, PEPPER MS, ADLERCREUTZ H, MONTESANO R, NAWROTH PP, SCHWEIGERER L. (1994). The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237-239.
18. FREI-JONES M, MCKINSTRY RC, PERRY A, LEONARD JR, PARK TS, RUBIN JB. (2008). Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neuros-Pediatr 2: 125-129.
19. FRIEDEN IJ, EICHENFIELD LF, ESTERLY NB, GERONEMUS R, MALLORY SB, THE GUIDELINES/OUTCOMES COMMITTEE. (1997). Guidelines of care for hemangiomas of infancy. J Am Acad Dermatol 37: 631-637.
20. GOTTSCHLING S, SCHNEIDER G, MEYER S, REINHARD H, DILL-MUELLER D, GRAF N. (2006). Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 46: 239-242.
21. GRIMAL I, DUVEAU E, ENJOLRAS O, VERRET JL, GINIES JL. (2000). Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants. Arch Pediatrie 7: 163-167.
22. HAIK BG, KARCIOGLU ZA, GORDON RA, PECHOUS BP. (1994). Capillary hemangioma (infantile periocular hemangioma). Surv Ophthalmol 38: 399-426.
23. HAJIGHASEMI F.H. MA. (2009). In vitro sensitivity of leukemia cells to propranolol. J Clin Med Res 1: 144-149.
24. HASAN Q, TAN ST, XU B, DAVIS PF. (2003). Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin Exp Pharmacol P 30: 140-144.
25. HASAN Q, ROGER BM, TAN ST, GUSH J, DAVIS PF. (2000). Clusterin/ApoJ expression during the development of hemangioma. Hum Pathol 31: 691-697.
26. HAYOT C, FARINELLE S, DE DECKER R, DECAESTECKER C, DARRO F, KISS R, VAN DAMME M. (2002). In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 21: 417-425.
27. JIMENEZ-HERNANDEZ E, DUENAS-GONZALEZ MT, QUINTERO-CURIEL JL, VELASQUEZ-ORTEGA J, MAGANA-PEREZ JA, BERGES-GARCIA A, ARELLANO-GALINDO J. (2008). Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg 34: 640-647.
28. KOMOROWSKI J, JERCZYŃSKA H, SIEJKA A, BARAŃSKA P, ŁAWNICKA H, PAWŁOWSKA STEPIȨŃ. (2006). Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 78(22): 2558-63.
29. KULLENDORFF CM. (1997). Efficacy of bleomycin treatment for symptomatic hemangiomas in children. Pediatr Surg Int 12: 526-528.
30. LÉAUTÉ-LABRÈZE C, DUMAS DE LA ROQUE E, HUBICHE T, BORALEVI F, THAMBO JB, TAÏEB A. (2008). Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2649-2651.
31. MABETA P, PEPPER MS. (2009). A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 12: 81-90.
32. MABETA P, DAVIS PF. (2008). The mechanism of bleomycin in inducing haemangioma regression. S Afr Med J 98: 538-539.
33. MARTINS AG. (1970). Hemangioma and thrombocytopenia. J Pediatr Surg 5: 641-648.
34. MCKAY TL, GEDEON DJ, VICKERMAN MB, HYLTON AG, RIBITA D, OLAR HH, KAISER PK, PARSONS-WINGERTER P. (2008). Selective inhibition of angiogenesis in small blood vessels and decrease in vessel diameter throughout the vascular tree by triamcinolone acetonide. Invest Ophthalmol Vis Sci 49: 1184-1190.
35. MUIR T, KIRSTEN M, FOURIE P, DIPPENAAR N, IONESCU GO. (2004). Intralesional bleomycin injection (IBI) for hemangiomas and congenital vascular malformations. J Pediatr Surg 39: 1735-1736.
36. MULLIKEN JB and ENJOLRAS O. (2004). Congenital hemangiomas and infantile hemangioma: Missing links. J Am Acad Dermatol 50: 875-882.
37. MULLIKEN JB and GLOWACKI J. (1982). Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg 69: 412-422.
38. MULLIKEN JB, ZETTER BR, FOLKMAN J. (1982). In vitro characteristics of endothelium from hemangiomas and vascular malformations. Surgery 92: 348-353.
39. NORTH PE, WANER M, BRODSKY MC. (2002). Are infantile hemangioma of placental origin? Ophthalmology 109: 223-224.
40. NORTH PE, WANER M, MIZERACKI A, MIHM MC. (2000). GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31: 11-22.
41. OIKAWA T, HIROTANI K, OGASAWARA H, KATAYAMA T, ASHINO-FUSE H, SHIMAMURA M, IWAGUCHI T, NAKAMURA O. (1990). Inhibition of angiogenesis by bleomycin and its copper complex. Chem Pharm Bull 38: 1790-1792.
42. PANDEY A, GANGOPADHYAY AN, UPADHYAY VD. (2008). Evaluation and management of infantile hemangioma: An overview. Ostomy Wound Manag 54: 16-18.
43. PANDEY A, GANGOPADHYAY AN, GOPAL SC, KUMAR V, SHARMA SP, GUPTA DK, SINHA CK. (2009). Twenty years' experience of steroids in infantile hemangioma-a developing country's perspective. J Pediatr Surg 44: 688-694.
44. PEPPER MS. (1997). Manipulating angiogenesis. from basic science to the bedside. Arterioscl Thromb Vas 17: 605-619.
45. PEREZ PAYAROLS J, PARDO MASFERRER J, GOMEZ BELLVERT C. (1995). Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med 333: 369.
46. PIENAAR C, GRAHAM R, GELDENHUYS S, HUDSON DA. (2006). Intralesional bleomycin for the treatment of hemangiomas. Plast Reconstr Surg 117: 221-226.
47. RAIG ET, JONES NB, VARKER KA, BENNIGER K, GO MR, BIBER JL, LESINSKI GB, CARSON WE,3rd. (2008). VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J. Interfer. Cytokine Res. 28: 553-561.
48. RAZON MJ, KRALING BM, MULLIKEN JB, BISCHOFF J. (1998). Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 5: 189-195.
49. REGNIER S, DUPIN N, LE DANFF C, WASSEF M, ENJOLRAS O, ARACTINGI S. (2007). Endothelial cells in infantile haemangiomas originate from the child and not from the mother (a fluorescence in situ hybridization-based study). Br J Dermatol 157: 158-160.
50. SANS V, DE LR, BERGE J, GRENIER N, BORALEVI F, MAZEREEUW-HAUTIER J, LIPSKER D, DUPUIS E, EZZEDINE K, VERGNES P, et al., (2009). Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics 124:e423-431.
51. SARIHAN H, MOCAN H, YILDIZ K, ABES M, AKYAZICI R. (1997). A new treatment with bleomycin for complicated cutaneous hemangioma in children. Eur J Pediatr Surg 7: 158-162.
52. SGONC R, FUERHAPTER C, BOECK G, SWERLICK R, FRITSCH P, SEPP N. (1998). Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Aller Imm 117: 209-214.
53. SOMMERS SMITH SK and SMITH DM. (2002). Beta blockade induces apoptosis in cultured capillary endothelial cells. In vitro Cell Dev B-An 38: 298-304.
54. TAKAHASHI K, MULLIKEN JB, KOZAKEWICH HP, ROGERS RA, FOLKMAN J, EZEKOWITZ RA. (1994). Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93: 2357-2364.
55. TAN ST, VELICKOVIC M, RUGER B, DAVIS PF. (2000). Cellular and Extracellular markers of hemangioma. Plast Reconstr Surg 106: 529-538.
56. VLAHOVIC A, SIMIC R, DJOKIC D, CERAN C. (2009). Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: A case report. J Pediat Hematol Onc 31: 858-860.
57. WANG L, WU W, SUN H, WU X, QIN L, LIU Y, LIU K, TANG Z. (2003). Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 7: 587-594.
58. WILSON MW, HOEHN ME, HAIK BG, RIEMAN M, REISS U. (2007). Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 114: 1007-1011.
59. YANG Y, SUN M, CHENG X, HU X, ZHANG P, MA Q, LI J, TIAN L, LEI D. (2009). Bleomycin A5 plus dexamethasone for control of growth in infantile parotid hemangiomas. Oral Surg Oral Med O 108: 62-69.
60. ZAREM H.A. EDGERTON MT. (1967). Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 39: 76-83.
61. ZHANG G, YI C, LI X, LIANG Z, WANG R, LIU D, ZHANG L, MENG C, GUO S. (2008). Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9. Med Hypotheses 70: 815-818.
62. ZHANG Q, KANG X, ZHAO W. (2006). Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on lewis lung carcinoma. Biochem Biophys Res Commun 342: 824-828.
63. ZHENG JW, YANG XJ, WANG YA, HE Y, YE WM, ZHANG ZY. (2009). Intralesional injection of pingyangmycin for vascular malformations in oral and maxillofacial regions: An evaluation of 297 consecutive patients. Oral Oncol 45: 872-876.
64. ZVULUNOV A, METZKER A. (2002). Hemangiomas and vascular malformations: Unapproved treatments. Clin Dermatol 20: 660-667